Recently, the addition of pembrolizumab to platinum-based chemotherapy was used in treatment-naïve advanced NSCLC patients with a PD-L1 expression of ≥1% [16,17] Similarly, other IOs have demonstrated a clear improvement in outcomes as a monotherapy or in combination of ICIs with chemotherapy versus chemotherapy alone, regardless of PD-L1 expression levels [16,17,18,19]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.